Healthcare Nanotechnology Market Report 2025

This Healthcare Nanotechnology market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The healthcare nanotechnology market size has grown rapidly in recent years. It will grow from $344.23 billion in 2024 to $389.11 billion in 2025 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to advancements in nanomaterials, nanomedicine research, regulatory support, investment in research and development, nanostructured biomaterials.

The healthcare nanotechnology market size is expected to see rapid growth in the next few years. It will grow to $723.18 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to theranostics development, nanoparticles for gene therapy, biocompatible nanomaterials, nano-enabled surgical tools, nanoscale therapeutic agents, global health emergency preparedness. Major trends in the forecast period include diagnostic nanodevices, biosensors and imaging, nanorobotics and nanosurgery, personalized medicine, public awareness and education therapeutic applications.

The rising incidence of cancer cases is anticipated to drive the growth of the healthcare nanotechnology market. Nanotechnology represents a promising approach to cancer treatment, offering the potential for more personalized therapies for various diseases, including cancer. The global prevalence of cancer continues to rise. For example, in 2023, the American Cancer Society estimated that there would be 1,958,310 new cancer diagnoses and 609,820 cancer-related deaths in the United States. These statistics underscore the persistent challenges in cancer prevention and treatment, despite advancements in medical technology and early detection methods. They highlight the urgent need for ongoing research and effective healthcare strategies to address cancer effectively. Consequently, the increasing number of cancer cases is fueling the growth of the healthcare nanotechnology market.

Growing incidences of diabetes and obesity are expected to propel the growth of the healthcare nanotechnology market going forward. Diabetes refers to a condition that develops when blood glucose levels are too high, and obesity refers to the condition of having a body mass index of 30 or more. Healthcare nanotechnology offers targeted drug delivery and precision medicine approaches to manage diabetes and obesity, improving treatment efficacy while minimizing side effects. For instance, in June 2022, according to the International Diabetes Federation, a Belgium-based diabetes federation, the prevalence of diabetes had increased to 10. 5% worldwide, with over half (44. 7%) of people still undiagnosed. According to IDF predictions, 783 million adults, or one in eight people, will have diabetes by 2045. This would represent a 46% rise, more than double the projected population growth for the same period (20%). Furthermore, in March 2022, according to the World Health Organization, a Switzerland-based agency, 650 million adults, 340 million teenagers, and 39 million children will be obese. This quantity is still rising, and the WHO predicts that by 2.02 trillion adults and children will become overweight or obese. Therefore, growing incidences of diabetes and obesity are driving the growth of the healthcare nanotechnology market.

Strategic collaboration between companies is a key trend gaining popularity in the healthcare nanotechnology market. Companies involved in healthcare nanotechnologies are undergoing partnerships and collaboration to develop new technologies and products. In January 2022, NaNotics, a US-based medical company, collaborated with the Mayo Clinic to develop a cancer treatment known as NaNots. The collaboration will involve NaNotics sharing its nano-depletion platform with Mayo researchers, while the Mayo Clinic will provide its own PD-L1 antibody and a transgenic mouse model that provides human sPD-L1. Mayo Clinic is a US-based clinic dedicated to providing patient care, education, and research in various fields of medicine, including nanomedicine.

Major companies operating in the healthcare nanotechnology market are increasing their focus on introducing nanotechnology-based gel serums to gain a competitive edge in the market. Nanotechnology-based gel serums are products that incorporate nanoscale particles or delivery systems to enhance the absorption and effectiveness of active ingredients. For instance, in March 2023, ENTOD Pharmaceuticals, an India-based healthcare company, launched Eyecirque, a nanotechnology-based under-eye product, in India. Eyecirque is formulated with a cutting-edge, 100% plant-based biocellular composition, featuring vitamin A, C, and E complexes, anti-aging antioxidants, skin-brightening agents, and naturally occurring ultra-moisturizing elements that are rapidly absorbed into the skin around the eyes at a nano-molecular level. It stands as the world's first gel serum of its kind, utilizing nanotechnology to address concerns such as wrinkles, hollowness, hollow eyelids, and dark circles under the eyes.

In January 2024, GenEdit, Inc., a US-based biotechnology firm, announced a multiyear collaboration and licensing agreement with Genentech to develop innovative nanoparticles for the delivery of genetic medicines intended to treat autoimmune diseases. This partnership will utilize GenEdit's NanoGalaxy platform, emphasizing the discovery of hydrophilic nanoparticles (HNPs) for nucleic acid-based therapies. Genentech, also based in the US, is a biotechnology corporation that specializes in healthcare nanotechnology.

Major companies operating in the healthcare nanotechnology market include Pfizer Inc., Johnson & Johnson Inc., Abbott Laboratories, Merck & Company Inc., Union Chimique Belge S. A, Teva Pharmaceutical Industries Ltd., Sanofi SA, Taiwan Liposome Company Ltd., GE Healthcare Technologies Inc., Mallinckrodt plc, Leadiant Biosciences, Luminex Corporation, Bristol-Myers Squibb Company, CytImmune Sciences Inc., Nanobiotix, Starpharma Holdings Limited, Copernicus Therapeutics Inc., NanoCarrier Co. Ltd, LiPlasome Pharma ApS, Nami Therapeutics Corp., Nanospectra Biosciences Inc., Spago Nanomedical AB, Nanobiosym Inc., Nanoviricides Inc., Nanosys Inc., Nanocarrier Co. Ltd., Nanocyl SA, Nanogen Pvt. Ltd.

North America was the largest region in the healthcare nanotechnology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the healthcare nanotechnology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the healthcare nanotechnology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Healthcare nanotechnology refers to the area of science that combines nanotechnology with drugs or diagnostic molecules to improve the performance of specific cells or tissues. These materials are produced on a nanoscale level and are safe to inject into the body. Nanotechnologies can greatly enhance medical diagnostics by making them more affordable and practical.

The main types of healthcare nanotechnology include organic, inorganic, and carbon-based. Healthcare nanotechnology is used for various diseases such as cardiovascular, oncological, neurological, orthopedic, and infectious diseases. The main applications of healthcare nanotechnology include drug delivery, biomaterials, active implants, and tissue regeneration.

The healthcare nanotechnology market research report is one of a series of new reports that provides healthcare nanotechnology market statistics, including healthcare nanotechnology industry global market size, regional shares, competitors with healthcare nanotechnology market share, detailed healthcare nanotechnology market segments, market trends and opportunities, and any further data you may need to thrive in the healthcare nanotechnology industry. This healthcare nanotechnology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The healthcare nanotechnology market includes revenues earned by entities by targeting tumors, in drug delivery systems, and improving medical imaging. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.